Risk assessment of pulmonary infections in primary glomerular diseases treated with rituximab
The incidence of pulmonary infections within 6 months of RTX treatment in patients with PGDs was 15.85%. sALB is a protective factor against pulmonary infections, while age, C3, and eGFR are risk factors. The total dose of RTX, concomitant use of corticosteroids or immunosuppressants, and levels of sIgG, LYM, NEUT, and NPAR were not related to infection risk.
Authors
- Chunxia Yang (ORCID: https://orcid.org/0000-0002-5566-3990)
- Qi Li (ORCID: https://orcid.org/0000-0002-9144-148X)
Institutions
- Nanchang University (CN)
- First Affiliated Hospital of Nanchang University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-10-24
- DOI
- https://doi.org/10.3389/fimmu.2025.1646894
- Primary Topic
- Renal Diseases and Glomerulopathies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Nanchang University